APR U 2 2007

Docket No. 2629-4036

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

10/735,082

Confirmation No.:

1602

Applicant(s):

James G. Lazar, et al.

Group Art Unit:

1631

Examiner:

TBA

Filed:

December 11, 2003

Customer No.:

27123

For:

IMMUNOLOGICAL DETECTION OF RNA: DNA HYBRIDS ON MICROARRAYS

EXPRESS MAIL CERTIFICATE

Mail Stop Amendments Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Express Mail Label No.: EV 825 701 385 US

Date of Deposit: April 2, 2007

I hereby certify that the following attached paper(s) and/or fee

- 1. Supplemental Information Disclosure Statement (3 pages);
- 2. Form PTO-1449A (1 pg.) with 1 US Patent cited reference (not included) and 15 foreign cited references;
- 3. Form PTO-1449 B (4 pgs.) with 46 cited non-patent references; and
- 4. Return receipt postcard.

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Jafet Cotto

(Typed or printed name of person mailing papers(s) and/or fee)

(Signature of person mailing paper(s) and/or fee)

Correspondence Address:

MORGAN & FINNEGAN, L.L.P. 3 World Financial Center New York, NY 10281-2101 (212) 415-8700 Telephone (212) 415-8701 Facsimile

Docket No. 2629-4036

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

10/735,082

Confirmation No.:

1602

Applicant(s):

James G. Lazar, et al.

Group Art Unit:

Examiner:

1631 TBA

Filed:

December 11, 2003

Customer No.:

27123

For:

IMMUNOLOGICAL DETECTION OF RNA:DNA HYBRIDS ON MICROARRAYS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

l .		For each of the following items listed on the enclosed copy of Form PTO-1449B that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:
		Khrapko, et al., "Hybridization of DNA with Oligonucleotides Immobilized in Gel: A Convenient Method for Detecting Single Base Substitutions," Mol Biol (Mosk) (USSR) 25(3):718-730 (translation page No. 581-591) (1991)
2.		For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.
3.		Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No, filed
		·
1.	\boxtimes	No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:

		37 C.F.R. §1.97(b)(1), within three months of the filing date of a national application other than a CPA; or
		37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or
	\boxtimes	37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or
		37 C.F.R. §1.97(b)(4) before the mailing date of a first office action after the filing of an RCE under §1.114.
5.	since in para Allowa	is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified agraph 4 above but before the mailing date of a final action or a Notice of ance (where there has been no prior final action), and is accompanied by one of tifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.
6.	it is be paragr	is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since sing filed in compliance with 37 C.F.R. §1.97(c), after the period specified in aph 4 above but before the mailing date of a final action or a notice of nce (where there has been no prior final action):
		A check in the amount of \$180.00 is enclosed in payment of the fee.
		Charge the fee to Deposit Account No. <u>13-4500</u> , Order No A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
7.	it is be action	is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since ing filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final or a notice of allowance, whichever comes first, but before payment of the issued is accompanied by:
		ne of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 slow; and
		e fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11 clow.
8.	This In	nformation Disclosure Statement is being filed in compliance with:
	a. 🗌	37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);
	b. 🗌	37 C.F.R. §1.313(c)(2) or §1.313(c)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant application and is accompanied by the

Docket No. 2629-4036 Serial No. 10/735,082

		C.F.R. §1.17(h).
	c. 🗌	The fee due under 37 C.F.R. §§1.17(h) is paid as set forth in paragraph 11 below.
9.	Statem	by certify that each item of information contained in this Information Disclosure nent was first cited in a communication from a foreign patent office in a erpart foreign application not more than three months prior to the filing of this nation Disclosure Statement.
	filed h counte was kr	by certify that no item of information in the Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a expart foreign application or, to my knowledge after making reasonable inquiry, nown to any individual designated in §1.56(c) more than three months prior to ing of this Information Disclosure Statement.
10.		ocument is accompanied by a Search Report Communication which was n a corresponding PCT or Foreign counterpart application
11.		ck in the amount of \$ is enclosed in payment of the fees due under 37. \$\\$1.17(h) and 1.17(p).
	13-450	e the fees due under 37 C.F.R. §§1.17(h) and 1.17(p) to Deposit Account No. 00, Order No A DUPLICATE COPY OF THIS SHEET IS CHED.
X	require Depos	ommissioner is hereby authorized to charge any additional fees which may be ed for this Information Disclosure Statement, or credit any overpayment to sit Account No. <u>13-4500</u> , Order No. <u>2629-4036</u> . A DUPLICATE COPY OF SHEET IS ATTACHED.
		Respectfully submitted, MORGAN & FINNEGAN, L.L.P.
Dated: <u>A</u>	<u>pril 2, 2</u>	By: Lucy Won Evelyn M. Kwon Registration No. 54,246
Correspo	ndence .	Address:
		NNEGAN, L.L.P.
		al Center
	•	10281-2101 Telephone
` /		Facsimile

ADD 11 2 70	ny 🏂				ey Docket:	<u> </u>	Serial N		
APRUZE		DRM PTO-1449A		2629-4 Applic			10/735,	082	
PEODM	8	ON DISCLOSURE CIT	ration	James	G. Lazar, et al.		·		
HADEA		N DISCLOSURE CIT	ATION	Filing	Date: ber 11, 2003		Group 2	Art Ui	nit:
		U.S.	PATEN		ICATION DOC	UMEN	-		
Examiner	Patent/Publication Number				ion/Issue Date		Name		Filing Data
Initial	1.	6,686,151		February 3		Lazar	ar et al.		Filing Date November 6, 2000
									,
2			FORE	IGN PATI	ENT DOCUME	NTS			
Examiner			Pul	blication		<u></u>	Сору		<u></u>
Initial_	2.	Patent Number EP 0 288 737		Date ov. 1988	Country EP	7	Filed		Translation Yes □ No □ Abstract ☑N/A
				Mar. 1997	EP		⊠ Yes	<u> </u>	Yes □ No ☒ Abstract □N/A
	3.	EP 0 480 289 B1						ļ	
	4.	GB 2 279 954 A		an. 1995	GB		⊠ Yes	 	'es □ No □ Abstract ⊠N/A
	5.	JP 04-4267897 A		ep. 1992	JP		⊠ Yes	 	'es □ No ☒ Abstract □N/A
	6.	WO 93/10263	27 N	May 1993	WO		⊠ Yes	Y	'es □ No □ Abstract ⊠N/A
	7.	WO 96/24694	15 A	Aug. 1996	WO		⊠ Yes	□ Y	es □ No □ Abstract ☑N/A
	8.	WO 97/10364	20 N	/lar. 1997	WO	···	⊠ Yes	ПΥ	'es □ No □ Abstract ⊠N/A
	9.	WO 97/31256 A2	28 A	aug. 1997	wo		⊠ Yes	ПΥ	'es □ No □ Abstract ⊠N/A
	10.	WO 97/31256 A3	28 A	Aug. 1997	wo		⊠ Yes	ПΥ	es □ No □ Abstract ⊠N/A
	11.	WO 99/29909	17 J	un. 1999	wo		⊠ Yes	🗆 Y	es □ No □ Abstract ⊠N/A
	12.	WO 99/32654	1 Ju	l. 1999	wo		⊠ Yes	ПΥ	'es □ No □ Abstract ⊠N/A
	13.	WO 99/36571	22 J	ul. 1999	wo		⊠ Yes	□Y	'es □ No □ Abstract ⊠N/A
	14.	WO 99/39001	5 Aı	ıg. 1999	wo		⊠ Yes	□ Y	'es □ No □ Abstract ⊠N/A
	15.	WO 99/40224	12 A	ug. 1999	wo		⊠ Yes	□ Y	'es □ No □ Abstract ⊠N/A
	16.	WO 00/60116	12 C	Oct. 2000	wo		⊠ Yes	□ Y	'es □ No □ Abstract ⊠N/A
							☐ Yes	□Y	'es No Abstract N/A
							☐ Yes	ПΥ	es No Abstract N/A
							☐ Yes	□ Y	es No Abstract N/A
							☐ Yes	□Y	'es □ No □ Abstract □N/A
		L	I		<u>. </u>		 	1	· - · · · · · · · · · · · · · · · · · ·

Examiner		Date Considered	
EXAMINER:	Initial if reference considered, whether or not citation is in conf Draw line through citation if not in conformance and not considered include copy of this form with next communication to Applicant	lered.	
			TX / 00 / TO 1 00 / Y

				1 age 1 of
			Attorney Docket:	Serial No.:
	FORM F	PTO-1449B	2629-4036	10/735,082
			Applicant:	
RMATION DISCLOSURE			James G. Lazar, et al.	
	T/2g	ATION	Filing Date:	Group Art Unit:
1 100 112	3007		December 11, 2003	1631
A			NT LITERATURE DOCUMEN	
Expriner Initial PAO	No.1	Include name of the author (in Ca journal, serial, symposium, ca	APITAL LETTERS), title of the articl atalog, etc.), date, page(s), volume-iss published.	e (when appropriate), title of the item (book, magazine, sue number(s), publisher, city and/or country where
	1.	Arnold et al., "Assay For Chem., 35/8, 1588-1594	_	-Ester-Labeled DNA Probes," Clin.
-				Ithe Listeria Monocytogenes PCR and
		Simple Immunoenzymati	c Assay of the Product Usi	ng Anti-RNA:DNA Antibodies" Appl.
	2.	Environ. Microbiol. 60:3	48-352.	
		Boguslawski, et al., "Cha	racterization of monoclona	I antibody to DNARNA and its
	3.			anol. Methods 89:123-130 1986.
				Biotinylated RNA Probes: A Study of
	4.			Hybrids" Anal. Biochem. 181:96-105.
				Biotinylated RNA Probes: A Study of
			nal Antibody to DNA-RNA	Hybrids" Anal. Biochem. 198:217
	5.	(Published erratum).		
				in an Enzyme Immunoassay Using a
	6.			Anal. Biochem. 81:153-162.
	_			enger RNA by Solution Hybridization
	7.		ay" J. Biol. Chem. 265:1160	
				man Papillomaviruses 16 and 18 in
				Enzyme Immunoassay for DNA-RNA
	8.		ion Hybridization" J. Clin.	
				scent, and Enzymatic Amplification Detection of DNA-RNA Hybrids," J.
	9.	Clin. Microbiol. 27(5):10		belection of Diva-Kiva Hybrids, J.
	9.			ical Diagnosis- Where Do We Stand?
	10.	Features, Vol. 57, No. 4,		ilear Diagnosis- where Do we stand:
	10.			od for Multiplex Detection of Low
				Biology, Vol. 292, pages 251-262,
	11.	September 19, 1999.		51010BJ, v oii 2 5 2 , puges 201 202,
	111		hybridization: A method f	or the isolation of cloned DNAs that
	12.			72(10):3961-3965 (1975).
				polymorphisms by hybridization with
	13.			cids Res. 22(24):5456-5465 (1994).
				ractical Approach (IRL Press Limited,
	14.	Oxford, England. 1985).	,	
	15.		nmobilized Affinity Licend	s (Academic Press, New York), 1992.
Examiner	13.	1 Termanson, et al., eus. II	Date	101K), 1772.
LAGIIIIIICI	1		Date	1

Considered

Signature

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

			Attorney Docket:	Serial No.:		
	FORM P	PTO-1449B	2629-4036	10/735,082		
INFORMATION DISCLOSURE			Applicant:			
			James G. Lazar, et al.			
	CITA	ATION	Filing Date:	Group Art Unit:		
			December 11, 2003	1631		
		NON PATE	NT LITERATURE DOCUMENT	rs		
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
		Ishikawa et al "Enzyme	e-Labeling of Antibodies and	their Fragments for Enzyme		
	16.			. Immunoassay 4(3): 209-327 (1983).		
	10.			nucleotides," Ann. Rev. Biochem.		
	17.	53:323-356 (1984).	•			
			•	ckwell Scientific Publications," 209-		
	18.	216 and 241-242 (1982).				
		Khrapko, et al., "Hybridi	zation of DNA with Oligonu	cleotides Immobilized in Gel: A		
				tutions," Mol Biol (Mosk) (USSR)		
	19.	25(3):718-730 (translatio	n page No. 581-591) (1991)			
				nd Poly(I)-Poly(dC) as Immunogens for		
the Induction of Antibo			ies to RNA-DNA Hybrids,"	Mol. Immunology 19(3):413-420		
20. (1982).						
				r Jejuni in Food and Poultry Viscera		
		, ,	Separation and Microtitre Hy	ybridization" J. Appl. Microbiol.		
***************************************	21.	83:641-651.				
		Lazar et al., 1999 "Hybrid Capture R: a Sensitive Signal Amplification-based				
		1	-	ation of Human Viral and Bacterial		
	22.	Pathogens" J. Clin, Ligar				
			on analyses of arrayed cDN	A libraries. Trends in Genetics vol. 7,		
	23.	pp. 314-317 (1991).				
				FDNA, RNA, and DNA-RNA Hybrid		
		Duplexes: Relationship v	vith Base Composition and S	Structure," Biochemistry 34:10807-		
	24.	10815 (1995).				
			sion monitoring by hybridization to high-density oligonucleotide			
			ure Biotechnology, vol. 14, pp. 1675-1680.			
		Maldonado-Rodriguez et	al, Hybridization of Glass-T	Cethered Oligonucleotide Probes to		
Target Strands Preanne			ed with Labeled Auxiliary C	Oligonucleotides, 1999, Molecular		
	26.	Biotechnology, vol. 11, p	pp. 1-12.			
			ar Cloning: A Laboratory Ma	anual (New York, Cold Spring Harbor		
	27.	Laboratory, 1982).				
		Maskos et al., "Oligonuc	leotide Hybridizations On G	lass Supports: A Novel Linker For		
		Oligonucleotides Synthes	sis and Hybridisation Proper	ties of Oligonucleotides Synthesized In		
	28.	Situ," Nucleic Acids Rese	earch 20:1679-1684 (1992).			

Date

Considered

Examiner Signature

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

			Attorney Docket:	Serial No.:		
FORM PTO-1449B			2629-4036	10/735,082		
			Applicant:			
INFO	RMATIO	N DISCLOSURE	James G. Lazar, et al.			
	CITA	ATION	Filing Date:	Group Art Unit:		
			December 11, 2003	1631		
		NON PATE	NT LITERATURE DOCUMENT	'S		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
·4·		McGraw et al "Sequenc	e-Dependent Oligonucleotid	e-Target Duplex Stabilities: Rules from		
	29.			chniques 8(6):674-678 (1990).		
	ļ			listory and Applications," Bioconj.		
	30.	Chem. 1:2-12 (1990).		J. P. P. J.		
			encing RNA Transcripts Syn	thesized in Vitro from Plasmids		
	31.		e Promoters," Methods. Enz			
		Narang, et al., "Chemical	l Synthesis of Deoxyoligonu	cleotides by the Modified Triester		
	32.		mol. vol. 65, Chapter 61, pp.			
		Newman et al., 1989 "So	lution Hybridization and En	zyme Immunoassay for Biotinylated		
***************************************	33.			ll Culture" Mol. Cell Probes 3:375-382.		
			-	for rapid DNA sequence analysis,"		
	34.	Proc. Natl. Acad. Sci. USA 91(11):5022-5026 (1994).				
		Rychlik, et al., "Optimization of the annealing temperature for DNA amplification in vitro,"				
	35.	Nucleic Acids Res. 18(21):6409-6412 (1990).				
	2.5	Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edition (Cold Spring Harbor				
	36.	Laboratory Press, Cold Spring Harbor, N.Y.) 1989) Chapters 5, 6).				
	27	Schena, et al., "Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray," Science 270:467-470 (1995).				
	37.			y Hybridization to Oligoncleotides on a		
	38.	Large Scale," TIG March		by Hybridization to Offgone leotides on a		
	30.			nong DNA Fragments Separated by Gel		
	39.		Biol. (1975) 98, 503-517.	nong DIVA Tragments separated by Ger		
	1 37.			ization and melting on oligonucleotide		
	40.	1 / /		d. Sci. USA 92:6379-6383 (1995).		
***************************************		Stollar, B.D. and A. Rash	ntchian, 1987 "Immunochem	ical Approaches to Gene Probe Assays"		
	41.					
				genes in two Hawaiian Drosophila		
		species by monoclonal in	nmunological identification	of RNA-DNA hybrids in situ," Proc.		
	42.	Natl. Acad. Sci. USA 786	(6):3751-3754 (1981).			
				brids by affinity-based hybrid		
	43.					
		·				

Examiner	Date	
Signature	 Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FORM PTO-1449B INFORMATION DISCLOSURE CITATION			Attorney Docket:	Serial No.:
			2629-4036	10/735,082
			Applicant:	
			James G. Lazar, et al	
:	CITA	4110N	Filing Date: December 11, 2003	Group Art Unit:
			NT LITERATURE DOCU	
Examiner Initials*	Cite No. ¹			e article (when appropriate), title of the item (book, magazine, ime-issue number(s), publisher, city and/or country where hed.
		Taylor, ed. Protein Immo	bilization: Fundament	als and Applications, M. Dekker, New York,
	44.	1991.		
		Tominaga et al, Colorime	etric ELISA measurem	ent of specific mRNA on immobilized-
				erse transcription with biotinylated
	45.	mononucleotides, 1996, 6		
	46.			ation Hybridization Assay for Detection of 5" J. Clin. Microbiol. 27:120-125.
40. Human minimunodencien			7 11 43 1 (401010 1 1010	, VI CARRA MARIO (1010) 27,1120 120,
			-	
<u>,</u>				
······································				
			4	
·*************************************				

***************************************			***************************************	

	1			
Examiner	1	• •	Date	

Considered

Signature

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.